In a recent Phase 2 study, Torisel (temsirolimus) showed little ability to reduce blood and urine levels of abnormal monoclonal protein (known as “M” protein) in relapsed multiple myeloma patients. The results were published in the November issue of the journal Leukemia Research.

Despite recent advancement in treatment options, many myeloma patients relapse and experience disease progression. Therefore, the search continues for new alternatives to treat the disease, especially for patients where previous therapy has proved unsuccessful.

Torisel, a drug already approved for use in advanced renal cell carcinoma, shows…